Semaglutide
- Generic Name
- Semaglutide
- Brand Names
- Ozempic, Rybelsus, Wegovy
- Drug Type
- Small Molecule
- Chemical Formula
- C187H291N45O59
- CAS Number
- 910463-68-2
- Unique Ingredient Identifier
- 53AXN4NNHX
- Background
Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity. Other members of this drug class include Exenatide and Liraglutide. Semaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection in December 2017. Th...
- Indication
Semaglutide is indicated to improve glycemic control in adults diagnosed with type 2 diabetes mellitus, and is used as an adjunct to diet and exercise. However, semaglutide is not a suitable first-line drug for diabetes that has not been controlled by diet and exercise. In addition, it has not been studied in patients with pancreatitis. Semaglutide is not in...
- Associated Conditions
- BMI >27 kg/m2, Cardiovascular Events, Obesity, Type 2 Diabetes Mellitus
- Associated Therapies
- Chronic Weight Management therapy
O-SEMA-Fast: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Plan to Fast During Ramadan in the United Arab Emirates, Saudi Arabia, and Kuwait
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 288
- Registration Number
- NCT05716724
- Locations
- 🇰🇼
KOC Hospital, Ahmadi, Kuwait
🇸🇦Al Hammadi, Riyadh, Saudi Arabia
🇸🇦Dallah Hospital_Riyadh, Riyadh, Saudi Arabia
Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 600
- Registration Number
- NCT05714683
Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea
- First Posted Date
- 2023-01-19
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 600
- Registration Number
- NCT05689372
A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range
- First Posted Date
- 2023-01-05
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 32
- Registration Number
- NCT05671653
- Locations
- 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
- Conditions
- Interventions
- First Posted Date
- 2023-01-03
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 7000
- Registration Number
- NCT05669755
- Locations
- 🇹🇷
Bursa Il Saglik Mudurlugu Yuksek Ihtısas Egitim ve Arastirma Hastanesi, Bursa, Yildirim, Turkey
🇺🇸Univ of Alabama Birmingham, Birmingham, Alabama, United States
🇺🇸Chambliss Clinical Trials LLC, Montgomery, Alabama, United States
A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight
- Conditions
- Interventions
- First Posted Date
- 2022-12-13
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 513
- Registration Number
- NCT05649137
- Locations
- 🇺🇸
Univ of Alabama Birmingham, Birmingham, Alabama, United States
🇺🇸John Muir Physicians Network, Concord, California, United States
🇺🇸Velocity Clinical Research Westlake, Los Angeles, California, United States
A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)
- First Posted Date
- 2022-12-12
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1407
- Registration Number
- NCT05646706
- Locations
- 🇨🇦
Premier Clinical Trial Research Network (PCTRN), Hamilton, Ontario, Canada
🇺🇸Univ of Alabama Birmingham, Birmingham, Alabama, United States
🇺🇸Healthscan Clinical Trials,LLC., Montgomery, Alabama, United States
Acute Subcutaneous SemaglutidE in Acute Ischemic sTroke
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2023-04-25
- Lead Sponsor
- Aarhus University Hospital
- Target Recruit Count
- 380
- Registration Number
- NCT05630586
- Locations
- 🇩🇰
Aarhus University Hospital, Aarhus, Denmark
Comparison of Body Weight Change Through Different Smeglutide Administration Methods
- First Posted Date
- 2022-11-15
- Last Posted Date
- 2022-11-15
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT05616052
- Locations
- 🇨🇳
Shanghai Public Health Clinical Center, Shanghai, Shanghai, China
Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese
- Conditions
- Interventions
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 507
- Registration Number
- NCT05616013
- Locations
- 🇺🇸
Pinnacle Research Group, LLC, Anniston, Alabama, United States
🇺🇸Cullman Clinical Trials, Cullman, Alabama, United States
🇺🇸Indago Research & Health Center, Inc, Hialeah, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.